...
首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
【24h】

Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

机译:重组组织型纤溶酶原激活剂治疗的缺血性中风患者发生严重出血性转化的危险因素:欧洲-澳大利亚-急性急性中风研究(ECASS II)的二级分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) improves the outcome for ischemic stroke patients who can be treated within 3 hours of symptom onset. The efficacy of thrombolysis has been demonstrated despite an increased risk of severe hemorrhagic transformation (HT) in patients treated with rtPA. We performed an analysis of risk factors for severe HT in the second European-Australasian Acute Stroke Study (ECASS II). METHODS: HTs were classified by using clinical and radiological criteria as follows: hemorrhagic infarction (HI), parenchymal hemorrhage (PH), and symptomatic intracranial hemorrhage (SICH). Potential risk factors for HT were tested by stepwise logistic regression analysis, including rtPA-by-variable interactions. In addition, the distribution of bad outcome (modified Rankin score 5 to 6) at day 90 was stratified according to each category of HT. RESULTS: PH and SICH but not HI were associated with rtPA. Also, PH and SICH but not HI were more severe in rtPA-treated patients than in those receiving placebo. Risk factors for PH were rtPA, extent of parenchymal hypoattenuation on baseline CT, congestive heart failure, increasing age, and baseline systolic blood pressure. The risk of PH on rtPA was increased in older patients and in those who were treated with aspirin before thrombolysis. Risk factors for SICH were rtPA, congestive heart failure, extent of parenchymal hypoattenuation, and increasing age. The risk of SICH on rtPA was increased in patients who were treated with aspirin before thrombolysis. CONCLUSIONS: This secondary analysis of ECASS II has confirmed the importance of the extent of hypoattenuation as a risk factor for severe HT. The findings also suggest that older patients and those who have used aspirin before stroke are at higher risk of a severe HT on rtPA.
机译:背景与目的:重组组织纤溶酶原激活剂(rtPA)进行静脉溶栓治疗可改善缺血性卒中患者的症状,这些患者可在症状发作后3小时内得到治疗。尽管使用rtPA治疗的患者发生严重出血转化(HT)的风险增加,但已证明溶栓的功效。我们在第二项欧洲-澳大利亚-澳大利亚急性中风研究(ECASS II)中对严重HT的危险因素进行了分析。方法:按照临床和放射学标准对HTs进行分类:出血性梗死(HI),实质性出血(PH)和有症状的颅内出血(SICH)。 HT的潜在危险因素通过逐步logistic回归分析进行了测试,包括rtPA逐变量相互作用。此外,第90天的不良结局分布(改良的Rankin评分5至6)根据HT的每个类别进行了分层。结果:PH和SICH但HI与rtPA相关。而且,rtPA治疗的患者的PH和SICH而非HI较接受安慰剂的患者更为严重。 PH的危险因素是rtPA,基线CT实质性低衰减的程度,充血性心力衰竭,年龄增长和基线收缩压。老年患者和溶栓前接受阿司匹林治疗的患者,rtPA发生PH的风险增加。 SICH的危险因素是rtPA,充血性心力衰竭,实质性低衰减程度和年龄增长。溶栓前接受阿司匹林治疗的患者,rtPA发生SICH的风险增加。结论:ECASS II的二次分析已证实低衰减程度作为严重HT的危险因素的重要性。研究结果还表明,老年患者和中风前使用过阿司匹林的患者发生rtPA严重HT的风险更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号